CD274 and kidney cancer: These findings are in line with recently published results of clinical trials in kidney cancer, demonstrating superior progression-free survival and overall survival for an anti-VEGFR and anti-PD-L1 combinatorial approach both over sunitinib (28–30) and checkpoint inhibitor monotherapy (31).